Bioequivalence of Fixed-Dose Combinations of Dapagliflozin/Metformin Relative to Single Components in Healthy Subjects
David W. Boulton(AstraZeneca (Poland)), Frank LaCreta(Fox Chase Cancer Center), Steven C. Griffen(Io Therapeutics (United States)), Ming Chang, Catia Kitaura, Allyson Pollack(Bristol-Myers Squibb (United States)), Susan Lubin(Bristol-Myers Squibb (Germany))
Cited by 0
Related Papers
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
|Journal of Clinical Investigation|2009|1.7k
Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State
|The Journal of Clinical Endocrinology & Metabolism|2007|373
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295
Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes
|Diabetes Care|2013|289
Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
|Clinical Pharmacokinetics|2013|277